Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Signalling pathways as targets for anticancer drug development

G Powis1

  • 1Arizona Cancer Center, University of Arizona Health Sciences Center, Tucson 85724.

Pharmacology & Therapeutics
|April 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

PATHOME: an algorithm for accurately detecting differentially expressed subpathways.

Oncogene·2014
Same author

PI-3-Kinase inhibitors in colorectal cancer.

Current cancer drug targets·2010
Same author

In vitro metabolism of [(3)H]2,6-dinitrotoluene by human and rat liver.

Toxicology in vitro : an international journal published in association with BIBRA·2010
Same author

Adenine and pyridine nucleotide concentrations and relationships to 2,6-dinitrotoluene metabolism in cultured rat liver slices.

Toxicology in vitro : an international journal published in association with BIBRA·2010
Same author

Increased thioredoxin-1 inhibits SSAT expression in MCF-7 human breast cancer cells.

Biochemical and biophysical research communications·2003
Same author

DNA microarray reveals increased expression of thioredoxin peroxidase in thioredoxin-1 transfected cells and its functional consequences.

Advances in experimental medicine and biology·2002
Same journal

Harnessing multispecific antibodies for next-generation cancer treatments.

Pharmacology & therapeutics·2026
Same journal

Protein acetylation modification in tissue fibrosis: Opportunities and challenges.

Pharmacology & therapeutics·2026
Same journal

Nipocalimab and other FcRn blockers in neuromuscular disorders.

Pharmacology & therapeutics·2026
Same journal

C26:0-lysophosphatidylcholine in X-linked adrenoleukodystrophy.

Pharmacology & therapeutics·2026
Same journal

The CircRNA/miRNA axis in breast cancer: From molecular mechanisms to clinical translation.

Pharmacology & therapeutics·2026
Same journal

Glymphatic-meningeal lymphatic dysfunction in epilepsy: novel mechanistic insights and therapeutic avenues.

Pharmacology & therapeutics·2026
See all related articles

Targeting intracellular signaling pathways activated by oncogenes offers a new strategy for anticancer drug development. This review examines drugs that inhibit these pathways, including those in clinical trials and preclinical development.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Oncogenes drive cell growth and transformation through intracellular signaling pathways.
  • Targeting these pathways presents a promising strategy for novel anticancer drug development.
  • Inhibiting specific signaling components may be more effective than targeting oncogene products directly.

Purpose of the Study:

  • To review the potential of targeting intracellular signaling pathways for anticancer drug development.
  • To examine existing and emerging antiproliferative drugs that inhibit signaling targets.
  • To discuss challenges in developing this new class of anticancer therapeutics.

Main Methods:

  • Literature review of scientific publications.
  • Analysis of existing antiproliferative drugs and their mechanisms of action.

Related Experiment Videos

  • Evaluation of drugs in clinical trials and preclinical development targeting signaling pathways.

    • Main Results:

    • Several antiproliferative drugs demonstrate the ability to inhibit key signaling targets.
    • Anticancer drugs targeting signaling pathways are progressing through clinical trials and preclinical development.
    • The review identifies specific signaling pathways and their targeted inhibitors.

    Conclusions:

    • Targeting intracellular signaling pathways is a viable and evolving strategy in cancer therapy.
    • Further research and development are needed to overcome challenges in this therapeutic area.
    • This approach holds potential for more effective and less toxic cancer treatments.